Patents by Inventor Russell J. Shine

Russell J. Shine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
    Patent number: 6245765
    Abstract: The invention is directed to the mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, pharmaceutical compositions containing said ziprasidone mesylate dihydrates, and methods of adminsitering the ziprasidone mesylate dihydrates to treat psychotic diseases.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: June 12, 2001
    Assignee: Pfizer Inc
    Inventors: Frank R. Busch, Carol A. Rose, Russell J. Shine
  • Process for steroidal peracyl glycosides
    Patent number: 5606041
    Abstract: Processes for the synthesis of tigogenin beta-O-cellobioside heptaalkanoate which is an intermediate for the known hypo-cholesterolemic agent tigogenin beta-cellobioside. The process comprises reacting .alpha.-cellobiosyl bromide heptaalkanoate and .beta.-tigogenin in the presence of zinc fluoride or zinc cyanide under conditions capable of forming said tigogenyl .beta.-O-cellobioside heptaalkanoate. The analogous preparations of hecogenin .beta.-O-cellobioside heptaalkanoate 11-ketotigogenin .beta.-O-cellobioside heptaalkanoate, and diosgenin .beta.-O-cellobioside heptaalkanoate are also disclosed. The process provides both high .beta.-anomeric selectivity and high yields.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: February 25, 1997
    Assignee: Pfizer Inc.
    Inventors: Frank R. Busch, Kathleen D. Goggin, John F. Lambert, Russell J. Shine, Stanley W. Walinsky
  • Method for making steroidal peracyl glycosides
    Patent number: 5530107
    Abstract: Processes for the synthesis of tigogenin beta-O-cellobioside heptaalkanoate which is an intermediate for the known hypocholesterolemic agent tigogenin beta-cellobioside. The process comprises reacting .alpha.-cellobiosyl bromide heptaalkanoate and .beta.-tigogenin in the presence of zinc fluoride or zinc cyanide under conditions capable of forming said tigogenyl .beta.-O-cellobioside heptaalkanoate. The analogous preparations of hecogenin .beta.-O-cellobioside heptaalkanoate, 11-ketotigogenin .beta.-O-cellobioside heptaalkanoate, and diosgenin .beta.-O-cellobioside heptaalkanoate are also disclosed. The process provides both high .beta.-anomeric selectivity and high yields.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: June 25, 1996
    Assignee: Pfizer Inc.
    Inventors: Douglas J. M. Allan, Frank R. Busch, John F. Lambert, Russell J. Shine, Stanley W. Walinsky